Eli Lilly to Acquire DICE Therapeutics for ~$2.4B
Shots:
- Eli Lilly will acquire all outstanding shares of DICE for a purchase price of $48 per share in cash representing a premium of ~40% relative to DICE’s closing price in June 2023 with a total deal value of ~$2.4B. The transaction is expected to close in Q3’23
- DICE will use its DELSCAPE technology platform to develop novel oral therapeutic candidates, incl. oral IL-17 inhibitors which are currently in clinical development for the treatment of chronic diseases in immunology
- Additionally, DICE is also developing oral therapeutic candidates targeting the integrin α4ß7 for the treatment of inflammatory bowel disease
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Coherus BioSciences to Acquire Surface Oncology for ~$65M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
